SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Espes Daniel)
 

Search: WFRF:(Espes Daniel) > GABA induces a horm...

  • Espes, Daniel,1985-Uppsala universitet,Institutionen för medicinsk cellbiologi,Transplantation och regenerativ medicin,Science for Life Laboratory, SciLifeLab (author)

GABA induces a hormonal counter-regulatory response in subjects with long-standing type 1 diabetes

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-10-11
  • BMJ Publishing Group Ltd,2021
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-457935
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-457935URI
  • https://doi.org/10.1136/bmjdrc-2021-002442DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Introduction: Experimentally, gamma-aminobutyric acid (GABA) has been found to exert immune-modulatory effects and induce beta-cell regeneration, which make it a highly interesting substance candidate for the treatment of type 1 diabetes (T1D). In many countries, including those in the European Union, GABA is considered a pharmaceutical drug. We have therefore conducted a safety and dose escalation trial with the first controlled-release formulation of GABA, Remygen (Diamyd Medical).Research design and methods: Six adult male subjects with long-standing T1D (age 24.8 +/- 1.5 years, disease duration 14.7 +/- 2.2 years) were enrolled in an 11-day dose escalation trial with a controlled-release formulation of GABA, Remygen. Pharmacokinetics, glucose control and hormonal counter-regulatory response during hypoglycemic clamps were evaluated at every dose increase (200 mg, 600 mg and 1200 mg).Results: During the trial there were no serious and only a few, transient, adverse events reported. Without treatment, the counter-regulatory hormone response to hypoglycemia was severely blunted. Intake of 600 mg GABA more than doubled the glucagon, epinephrine, growth hormone and cortisol responses to hypoglycemia.Conclusions: We find that the GABA treatment was well tolerated and established a counter-regulatory response to hypoglycemia in long-standing T1D. Further studies regarding not only the clinical potential of Remygen for beta-cell regeneration but also its potential use as hypoglycemic prophylaxis are warranted. Trail registration number and EudraCT2018-001115-73.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Liljebäck, HannaUppsala universitet,Institutionen för medicinsk cellbiologi,Institutionen för medicinska vetenskaper(Swepub:uu)hanli106 (author)
  • Hill, HenrikUppsala universitet,Pediatrisk inflammations- och metabolismforskning samt barnhälsa(Swepub:uu)henhi662 (author)
  • Elksnis, AndrisUppsala universitet,Institutionen för medicinsk cellbiologi(Swepub:uu)andel994 (author)
  • Caballero-Corbalán, JoséUppsala universitet,Transplantation och regenerativ medicin(Swepub:uu)josca151 (author)
  • Carlsson, Per-OlaUppsala universitet,Institutionen för medicinsk cellbiologi,Transplantation och regenerativ medicin(Swepub:uu)perocarl (author)
  • Uppsala universitetInstitutionen för medicinsk cellbiologi (creator_code:org_t)

Related titles

  • In:BMJ Open Diabetes Research & Care: BMJ Publishing Group Ltd92052-4897

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view